Mankind Pharma Ltd. · NSE:MANKIND
Mankind Pharma — Q4 FY23 Earnings Presentation
24 slides from Mankind Pharma's earnings presentation, May 2023
Slide 1: Investor Presentation – Q4 FY23 & FY23
INVESTOR PRESENTATION – Q4 FY23 & FY23
Slide 2: Safe Harbour Statement
Safe Harbour Statement 2 The statements, are as on date and may contain forward-looking statements like the words “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate”, “project”, “will”, “may”, “targeting” and similar expressions regarding the financial position, business strategy, plans,
Slide 3: Mankind Pharma at a Glance
Mankind Pharma at a Glance 3 #1 Youngest #4 4 Rank in Prescriptions in Top 5 of the IPM* By value in the IPM* Consumer Healthcare Market Leadership over the last five years* brands ranked #1 in their categories* INR 8,749 Cr 97% 20 15,000+ FY23 Revenue Domestic revenue # of INR 100 Cr+ brand Field f
Slide 4: Q4 FY23 Financial Snapshot (Consolidated)
Q4 FY23 Financial Snapshot (Consolidated) 4 Segmental Revenue Break - Up • Revenue from Operations at INR 2,053 crore, up by 19% YoY 4% • Domestic revenue up by 18% YoY • Consumer Healthcare revenue up by 10% 8% YoY • EBITDA at INR 419 crore, up by 45% YoY with margin of 20.4% versus 16.8% in Q4 FY2
Slide 5: FY23 Financial Snapshot (Consolidated)
FY23 Financial Snapshot (Consolidated) 5 • Revenue from Operations at INR 8,749 crore, up Domestic focused business – 97% share by 12% YoY Domestic revenue up by 11% YoY 3% o Consumer Healthcare up by 17% YoY 8% • EBITDA at INR 1,913 crore, margin of 21.9% • PAT at INR 1,310 crore, margin of 15.0%
Slide 6: Domestic Business
Domestic Business 6 Strong growth in domestic revenue in Q4 FY23 FY23 growth at 1.3X of IPM growth INR Crore INR Crore 8,453 1,972 7,595 1,677 Q4 FY22 Q4 FY23 FY22 FY23 • Growth of 18% YoY in Q4FY23; 11% YoY in FY23 as against 7.9%* IPM growth o Ex Covid growth of 14% YoY in FY23 • Maintained 4th* R
Slide 7: Increasing share of chronic segment
1 Increasing share of chronic segment 7 Increasing share of chronic segment that has a higher price realisation and lifetime value 1.7 X outperformance to IPM chronic in Q4 FY23 and 1.3 X Consistent focus to increase chronic contribution* in FY23* 35 25 34 34 19 16 15 33 14 13 14 12 11 32 9 FY20 FY2
Slide 8: Volume driven growth with increasing reach
2 Volume driven growth with increasing reach 8 1.3X outperformance in faster growing metro & class I cities* Strong volume growth outperformance across years* Contribution from Metro and Class I cities % in FY23 Growth in 9% 11% Metro & 16.7% Class I 64% 53% 9.2% 9.7% IPM Mankind IPM Mankind 2.5% 1.
Slide 9: Growing franchise of scaled brands…
3 Growing franchise of scaled brands… 9 INR 100+ crore brands families have increased from 13 in FY20 to 20 in FY23* Brand Families > INR 50 Crore > INR 100 Crore > INR 200 Crore FY20 29 13 7 FY23 37 20 11 Change FY20-23 1.3X 1.5X 1.6X *As per IQVIA, MAT March 2023
Slide 10: ..Across a fast growing diversified portfolio
3 ..Across a fast growing diversified portfolio 10 Diversified Therapy Presence High Ranks across Acute and Chronic Areas Therapy Areas Rank in CVM Market Share in IPM (%) Neuro / CNS 3% Anti- Infectives Anti-Infectives 4 5.7 Others 9% 15% Cardiovascular 4 4.6 Pain / Gastrointestinal 5 4.5 Analgesic
Slide 11: Partnerships & acquisitions: To expand CVM presence
4 Partnerships & acquisitions: To expand CVM presence 11 In-licensed Brand Patented Brand Respiratory Device Co-Marketed Insulin NEPTAZ ® SITCOM ® COMBIHALE ® NOBEGLAR® In-licencing Acquired from Acquired from In collaboration with agreement with Panacea Biotec DRL Biocon Novartis First Indigenous F
Slide 12: M&A Update: Panacea Biotec's Domestic Business
M 4 M&A Update: Panacea Biotec’s Domestic Business 12 • Forayed into highly specialized chronic therapies such as Transplant and Oncology Strategic • Strengthened presence amongst specialists with strong and differentiated brands Rationale • Highly profitable business with superior margins Organ Tra
Slide 13: Building fast growing Consumer Healthcare franchise…
5 Building fast growing Consumer Healthcare franchise… 13 Consumer Healthcare Revenue (Q4 FY23) Consumer Healthcare Revenue (FY23) INR Crore INR Crore 152 692 589 138 Q4 FY22 Q4 FY23 FY22 FY23 • Consumer Business witnessed a growth of 10% YoY in Q4 FY23 and 17% YoY in FY23 • 4* consumer healthcare b
Slide 14: …with market leading brands
5 …with market leading brands 14 Dominant Brands in Consumer Healthcare #1 #1 #2 Condom Brand Pregnancy Test Kit Antacid Brand Brand #1 #8 #1 Emergency Vitamins, Minerals, Acne Brand Contraceptive Brand Nutrients Brand *As per IQVIA Retail, MAT March 2023
Slide 15: Strong corporate identity complements brand recall…
5 Strong corporate identity complements brand recall… 15 Strategically selected national and regional brand ambassadors Corporate Brand Ambassadors Consumer Healthcare Brand Ambassadors
Slide 16: …With targeted marketing initiatives
5 …With targeted marketing initiatives 16 Marketing and Visibility Initiatives Rural Awareness Drives “Shakti Awareness Program”: Collaborated with Asha “Mark of Strength” : Women’s day Print ads workers to drive awareness about pregnancy detection kits campaign to promote body positivity Gas-O-Fast
Slide 17: Exports Business
Exports Business 17 Revenue from Exports (Q4 FY23) Revenue from Exports (FY23) INR Crore INR Crore 81 296 49 187 Q4 FY22 Q4 FY23 FY22 FY23 • Exports business witnessed a growth of 63% YoY in Q4 FY23 and growth 58% YoY in FY23 • Focus on differentiated filings • New integrated API/formulation manufac
Slide 18: ESG: Organization wide focus on sustainable growth
ESG : Organization wide focus on sustainable growth 18 Target to become Plastic Neutral in FY24 and Carbon Neutral by 2030 Water Energy & Emission Social Circular Economy Sustainable Stewardship Actions • 19% Reduction in • 3.1% reduction in • Zero reportable • 100% Plastic waste • Under ESG Scope-
Slide 19: Key Financial Metrics: FY 20-23 (Consolidated)
Key Financial Metrics : FY 20-23 (Consolidated) 19 * ROE* ROCE* Net Cash* (INR crore) Dip on Dip on account of account of acquisition 50% 50% acquisition 1,772 41% 44% 34% 31% 1,366 23% 25% 958 412 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 ROE ROCE FY20 FY21 FY22 FY23 Cash Flow from Operations (INR cr
Slide 20: Key P & L Highlights (Consolidated)
Key P & L Highlights (Consolidated) 20 In INR Crore Q4 FY23 Q4 FY22 YoY % FY23 FY22 YoY % Revenue from Operations 2,053 1,726 19% 8,749 7,782 12% Gross Margin % 67.2% 67.6% 66.7% 68.9% EBITDA 419 290 45% 1,913 2,004 -5% EBITDA Margin % 20.4% 16.8% 21.9% 25.8% Other Income 48 34 42% 129 196 -34% Prof
Slide 21: Shareholding Pattern
Shareholding Pattern 21 Retail , 4.7% Others, 0.8% FPI & Bodies Shareholding Information Corporate, 16.2% BSE Ticker 543904 Mutual Funds , NSE Symbol MANKIND 1.8% Market Cap. (INR Crore)* 54,786 % Free Float 23.5 Promoters, Free Float Market Cap. (INR 76.5% 12,875 Crore) Shares Outstanding (crore) 4
Slide 22: Q4 FY23 Earnings Call Details
Q4 FY23 Earnings Call Details 22 Date 31st May, 2023 Time 12 Noon IST Dial – In Details Universal Access Numbers +91-22-62801214/ +91-22-71158115 Diamond Pass https://services.choruscall.in/DiamondPassRegistration/register?co nfirmationNumber=4134984&linkSecurityString=15dc37a210
Slide 23: Annexure – Formulas
Annexure – Formulas 23 • ROE = (Profit for the year) / (average total equity less cash) o Profit excludes interest income and gain on current investments measured at FVTPL • Adjusted ROE = (Adjusted profit for the year) / (average adjusted total equity less cash) o Profit excludes any M&A related im
Slide 24: Thank You
24 For more information please visit our website: https://www.mankindpharma.com Thank You For specific queries, contact: Ravi Kumar Agrawal – 011 - 46846700 Investor.relations@mankindpharma.com